A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Early signs suggest that Alkermes might have found a therapeutic window with its IL-2-targeting agent, ALKS 4230.
Promising but early data on PD-1 x CTLA-4 bispecifics from Macrogenics and Akeso add further weight to this approach.